Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;6(1):87-94.
doi: 10.1136/svn-2020-000332. Epub 2020 Sep 24.

Implementation of regional Acute Stroke Care Map increases thrombolysis rates for acute ischaemic stroke in Chinese urban area in only 3 months

Affiliations

Implementation of regional Acute Stroke Care Map increases thrombolysis rates for acute ischaemic stroke in Chinese urban area in only 3 months

Yi Sui et al. Stroke Vasc Neurol. 2021 Mar.

Abstract

Background: The rate of intravenous thrombolysis for acute ischaemic stroke remains low in China. We investigated whether the implementation of a citywide Acute Stroke Care Map (ASCaM) is associated with an improvement of acute stroke care quality in a Chinese urban area.

Methods: The ASCaM comprises 10 improvement strategies and has been implemented through a network consisting of 20 tertiary hospitals. We identified 7827 patients with ischaemic stroke admitted from April to October 2017, and 506 patients underwent thrombolysis were finally included for analysis.

Results: Compared with 'pre-ASCaM period', we observed an increased rate of administration of tissue plasminogen activator within 4.5 hours (65.4% vs 54.5%; adjusted OR, 1.724; 95% CI 1.21 to 2.45; p=0.003) during 'ASCaM period'. In multivariate analysis models, 'ASCaM period' was associated with a significant reduction in onset-to-door time (114.1±55.7 vs 135.7±58.4 min, p=0.0002) and onset-to-needle time (ONT) (169.2±58.1 vs 195.6±59.3 min, p<0.0001). Yet no change was found in door-to-needle time. Clinical outcomes such as symptomatic intracranial haemorrhage, favourable functional outcome (modified Rankin Scale ≤2) and in-hospital mortality remained unchanged.

Conclusion: The implementation of ASCaM was significantly associated with increased rates of intravenous thrombolysis and shorter ONT. The ASCaM may, in proof-of-principle, serve as a model to reduce treatment delay and increase thrombolysis rates in Chinese urban areas and possibly other highly populated Asian regions.

Keywords: stroke; thrombolysis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flowchart of the included study population. AIS, acute ischaemic stroke; ASCaM, Acute Stroke Care Map; tPA, tissue plasminogen activator.
Figure 2
Figure 2
Greater Shenyang Acute Stroke Care Map. The geographical locations of all 20 participating hospitals are displayed. The inset image is the greater Shenyang map illustrating individual administrative divisions. The figure was modified from https://en.wikipedia.org/wiki/Shenyang under licensing of CC0 1.0 universal public domain dedication.

References

    1. Wang W, Jiang B, Sun H, et al. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation 2017;135:759–71. 10.1161/CIRCULATIONAHA.116.025250 - DOI - PubMed
    1. Liu L, Wang D, Wong KSL, et al. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke 2011;42:3651–4. 10.1161/STROKEAHA.111.635755 - DOI - PubMed
    1. Wasay M, Khatri IA, Kaul S. Stroke in South Asian countries. Nat Rev Neurol 2014;10:135–43. 10.1038/nrneurol.2014.13 - DOI - PubMed
    1. Liu L, Liu J, Wang Y, et al. Substantial improvement of stroke care in China. Stroke 2018;49:3085–91. 10.1161/STROKEAHA.118.022618 - DOI - PubMed
    1. Wang Y, Li Z, Zhao X, et al. Effect of a multifaceted quality improvement intervention on hospital personnel adherence to performance measures in patients with acute ischemic stroke in China: a randomized clinical trial. JAMA 2018;320:245–54. 10.1001/jama.2018.8802 - DOI - PubMed

Publication types

Substances